Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fremanezumab for preventive treatment of chronic migraine (Japan, randomized, double-blind, placebo-controlled)
jRCT2080223667Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in chronic migraine comparing Fremanezumab monthly dosing (675/225/225 mg), Fremanezumab quarterly dosing (675 mg/placebo/placebo) and Placebo (3 arms). Primary endpoint: Efficacy of fremanezumab in chronic migraine prevention. Started Oct 2017; status: completed.
02
Drugs
fremanezumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on jRCT2080223667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223667.